A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
← catalyst calendarSponsored by Aligos Therapeutics (industry) · ALGS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
24actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-09 | actual | When the study began enrolling |
| Primary completion | 2025-07-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-07 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: Carbamazepine
- Drug: Itraconazole (Sporanox)
- Drug: ALG-000184
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration time curve [AUC]
measured Up to 24 days
Area under the concentration time curve [AUC]
measured Up to 29 days.
Time to maximum plasma concentration [Tmax]
measured Up to 29 days
Time to maximum plasma concentration [Tmax]
measured Up to 24 days
Maximum plasma concentration [Cmax]
measured Up to 29 days
Maximum plasma concentration [Cmax]
measured Up to 24 days
Minimum plasma concentration [Cmin]
measured Up to 24 days
Minimum plasma concentration [Cmin]
measured Up to 29 days
C0 [predose]
measured Up to 24 days
C0 [predose]
measured Up to 29 days
Half-life [t1/2]
measured Up to 24 days
Half-life [t1/2]
measured Up to 29 days
Permalink · ALGS's whole pipeline · Catalyst calendar · Every registered study · What changed